Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 64

1.

Steroid-Associated Side Effects in Patients With Primary Proteinuric Kidney Disease.

Oh GJ, Waldo A, Paez-Cruz F, Gipson PE, Pesenson A, Selewski DT, Kamil ES, Massengill SF, Lafayette RA, Modes M, Adler SG, Desmond H, Eikstadt R, Attalla S, Modi ZJ, Troost JP, Gipson DS.

Kidney Int Rep. 2019 Sep 9;4(11):1608-1616. doi: 10.1016/j.ekir.2019.08.019. eCollection 2019 Nov.

2.

Noninvasive Urinary Monitoring of Progression in IgA Nephropathy.

Yang JYC, Sarwal RD, Fervenza FC, Sarwal MM, Lafayette RA.

Int J Mol Sci. 2019 Sep 10;20(18). pii: E4463. doi: 10.3390/ijms20184463.

3.

Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy.

Fervenza FC, Appel GB, Barbour SJ, Rovin BH, Lafayette RA, Aslam N, Jefferson JA, Gipson PE, Rizk DV, Sedor JR, Simon JF, McCarthy ET, Brenchley P, Sethi S, Avila-Casado C, Beanlands H, Lieske JC, Philibert D, Li T, Thomas LF, Green DF, Juncos LA, Beara-Lasic L, Blumenthal SS, Sussman AN, Erickson SB, Hladunewich M, Canetta PA, Hebert LA, Leung N, Radhakrishnan J, Reich HN, Parikh SV, Gipson DS, Lee DK, da Costa BR, Jüni P, Cattran DC; MENTOR Investigators.

N Engl J Med. 2019 Jul 4;381(1):36-46. doi: 10.1056/NEJMoa1814427.

PMID:
31269364
4.

Increasing Options for First-Line Therapy in Primary FSGS?

Lafayette RA.

Kidney Int Rep. 2018 Oct 29;4(1):8-10. doi: 10.1016/j.ekir.2018.10.016. eCollection 2019 Jan. No abstract available.

5.

A rare case of Alport syndrome, atypical hemolytic uremic syndrome and Pauci-immune crescentic glomerulonephritis.

Tao J, Lieberman J, Lafayette RA, Kambham N.

BMC Nephrol. 2018 Dec 12;19(1):355. doi: 10.1186/s12882-018-1170-4.

6.

Clinical Characteristics and Treatment Patterns of Children and Adults With IgA Nephropathy or IgA Vasculitis: Findings From the CureGN Study.

Selewski DT, Ambruzs JM, Appel GB, Bomback AS, Matar RB, Cai Y, Cattran DC, Chishti AS, D'Agati VD, D'Alessandri-Silva CJ, Gbadegesin RA, Hogan JJ, Iragorri S, Jennette JC, Julian BA, Khalid M, Lafayette RA, Liapis H, Lugani F, Mansfield SA, Mason S, Nachman PH, Nast CC, Nester CM, Noone DG, Novak J, O'Shaughnessy MM, Reich HN, Rheault MN, Rizk DV, Saha MK, Sanghani NS, Sperati CJ, Sreedharan R, Srivastava T, Swiatecka-Urban A, Twombley K, Vasylyeva TL, Weaver DJ, Yin H, Zee J, Falk RJ, Gharavi AG, Gillespie BW, Gipson DS, Greenbaum LA, Holzman LB, Kretzler M, Robinson BM, Smoyer WE, Flessner M, Guay-Woodford LM, Kiryluk K; CureGN Consortium.

Kidney Int Rep. 2018 Aug 3;3(6):1373-1384. doi: 10.1016/j.ekir.2018.07.021. eCollection 2018 Nov.

7.

JAK-STAT signaling is activated in the kidney and peripheral blood cells of patients with focal segmental glomerulosclerosis.

Tao J, Mariani L, Eddy S, Maecker H, Kambham N, Mehta K, Hartman J, Wang W, Kretzler M, Lafayette RA.

Kidney Int. 2018 Oct;94(4):795-808. doi: 10.1016/j.kint.2018.05.022. Epub 2018 Aug 6.

8.

Cause of kidney disease and cardiovascular events in a national cohort of US patients with end-stage renal disease on dialysis: a retrospective analysis.

O'Shaughnessy MM, Liu S, Montez-Rath ME, Lafayette RA, Winkelmayer WC.

Eur Heart J. 2019 Mar 14;40(11):887-898. doi: 10.1093/eurheartj/ehy422.

PMID:
30085056
9.

Immunoglobulin A Nephropathy: Advances in Understanding of Pathogenesis and Treatment.

Lafayette RA, Kelepouris E.

Am J Nephrol. 2018;47 Suppl 1:43-52. doi: 10.1159/000481636. Epub 2018 May 31. Review.

10.

NephCure Accelerating Cures Institute: A Multidisciplinary Consortium to Improve Care for Nephrotic Syndrome.

Gipson DS, Selewski DT, Massengill SF, Modes MM, Desmond H, Lee L, Kamil E, Elliott MR, Adler SG, Oh G, Lafayette RA, Gipson PE, Sinha A, Bagga A, Pesenson A, Courtlandt C, Spino C, Eikstadt R, Pitter R, Attalla S, Waldo A, Winneker R, Carlozzi NE, Troost JP, Smokler I, Stone M.

Kidney Int Rep. 2017 Nov 28;3(2):439-446. doi: 10.1016/j.ekir.2017.11.016. eCollection 2018 Mar.

11.

Corticosteroids for IgA Nephropathy: TESTING for Benefit, Discovering Harm.

O'Shaughnessy MM, Lafayette RA.

JAMA. 2017 Aug 1;318(5):429-431. doi: 10.1001/jama.2017.9359. No abstract available.

PMID:
28763530
12.

Daratumumab yields rapid and deep hematologic responses in patients with heavily pretreated AL amyloidosis.

Kaufman GP, Schrier SL, Lafayette RA, Arai S, Witteles RM, Liedtke M.

Blood. 2017 Aug 17;130(7):900-902. doi: 10.1182/blood-2017-01-763599. Epub 2017 Jun 14.

PMID:
28615223
13.

Kidney Transplantation Rates Across Glomerulonephritis Subtypes in the United States.

OʼShaughnessy MM, Liu S, Montez-Rath ME, Lafayette RA, Winkelmayer WC.

Transplantation. 2017 Oct;101(10):2636-2647. doi: 10.1097/TP.0000000000001657.

PMID:
28207635
14.

Validating identification of patients with small vessel vasculitis, with or without renal involvement, using administrative healthcare records.

O'Shaughnessy MM, Cheng XS, Montez-Rath ME, Lafayette RA, Winkelmayer WC.

Clin Nephrol. 2017 Mar;87 (2017)(3):159-162. doi: 10.5414/CN109035. No abstract available.

PMID:
28102817
15.

A Randomized, Controlled Trial of Rituximab in IgA Nephropathy with Proteinuria and Renal Dysfunction.

Lafayette RA, Canetta PA, Rovin BH, Appel GB, Novak J, Nath KA, Sethi S, Tumlin JA, Mehta K, Hogan M, Erickson S, Julian BA, Leung N, Enders FT, Brown R, Knoppova B, Hall S, Fervenza FC.

J Am Soc Nephrol. 2017 Apr;28(4):1306-1313. doi: 10.1681/ASN.2016060640. Epub 2016 Nov 7.

16.

Kidney Transplantation Outcomes across GN Subtypes in the United States.

O'Shaughnessy MM, Liu S, Montez-Rath ME, Lenihan CR, Lafayette RA, Winkelmayer WC.

J Am Soc Nephrol. 2017 Feb;28(2):632-644. doi: 10.1681/ASN.2016020126. Epub 2016 Jul 18.

17.

Endoplasmic Reticulum Stress Predicts Clinical Response to Cyclosporine Treatment in Primary Membranous Nephropathy.

Tao J, Zhang W, Wen Y, Sun Y, Chen L, Li H, Li M, Li X, Lafayette RA, Li X.

Am J Nephrol. 2016;43(5):348-56. doi: 10.1159/000446293. Epub 2016 May 11. Erratum in: Am J Nephrol. 2016;44(1):84.

18.

Differences in Initial Hemodialysis Vascular Access Use Among Glomerulonephritis Subtypes in the United States.

O'Shaughnessy MM, Montez-Rath ME, Zheng Y, Lafayette RA, Winkelmayer WC.

Am J Kidney Dis. 2016 Apr;67(4):638-47. doi: 10.1053/j.ajkd.2015.11.019. Epub 2016 Jan 8.

PMID:
26774466
19.

Complete Remission in the Nephrotic Syndrome Study Network.

Gipson DS, Troost JP, Lafayette RA, Hladunewich MA, Trachtman H, Gadegbeku CA, Sedor JR, Holzman LB, Moxey-Mims MM, Perumal K, Kaskel FJ, Nelson PJ, Tuttle KR, Bagnasco SM, Hogan MC, Dell KM, Appel GB, Lieske JC, Ilori TO, Sethna CB, Fervenza FC, Hogan SL, Nachman PH, Rosenberg AZ, Greenbaum LA, Meyers KE, Hewitt SM, Choi MJ, Kopp JB, Zhdanova O, Hodgin JB, Johnstone DB, Adler SG, Avila-Casado C, Neu AM, Hingorani SR, Lemley KV, Nast CC, Brady TM, Barisoni-Thomas L, Fornoni A, Jennette JC, Cattran DC, Palmer MB, Gibson KL, Reich HN, Mokrzycki MH, Sambandam KK, Zilleruelo GE, Licht C, Sampson MG, Song P, Mariani LH, Kretzler M.

Clin J Am Soc Nephrol. 2016 Jan 7;11(1):81-9. doi: 10.2215/CJN.02560315. Epub 2015 Dec 10.

20.

Differences in initial treatment modality for end-stage renal disease among glomerulonephritis subtypes in the USA.

O'Shaughnessy MM, Montez-Rath ME, Lafayette RA, Winkelmayer WC.

Nephrol Dial Transplant. 2016 Feb;31(2):290-8. doi: 10.1093/ndt/gfv386. Epub 2015 Nov 25.

21.

Clinicopathological features of membranoproliferative glomerulonephritis under a new classification.

Nargund P, Kambham N, Mehta K, Lafayette RA.

Clin Nephrol. 2015 Dec;84(6):323-30. doi: 10.5414/CN108619.

PMID:
26445002
22.

Patient characteristics and outcomes by GN subtype in ESRD.

O'Shaughnessy MM, Montez-Rath ME, Lafayette RA, Winkelmayer WC.

Clin J Am Soc Nephrol. 2015 Jul 7;10(7):1170-8. doi: 10.2215/CJN.11261114. Epub 2015 Jun 19.

23.

A Multicenter Randomized Controlled Trial of Rituximab versus Cyclosporine in the Treatment of Idiopathic Membranous Nephropathy (MENTOR).

Fervenza FC, Canetta PA, Barbour SJ, Lafayette RA, Rovin BH, Aslam N, Hladunewich MA, Irazabal MV, Sethi S, Gipson DS, Reich HN, Brenchley P, Kretzler M, Radhakrishnan J, Hebert LA, Gipson PE, Thomas LF, McCarthy ET, Appel GB, Jefferson JA, Eirin A, Lieske JC, Hogan MC, Greene EL, Dillon JJ, Leung N, Sedor JR, Rizk DV, Blumenthal SS, Lasic LB, Juncos LA, Green DF, Simon J, Sussman AN, Philibert D, Cattran DC; Mentor Consortium group.

Nephron. 2015;130(3):159-68. doi: 10.1159/000430849. Epub 2015 Jun 12.

PMID:
26087670
24.

Red blood cell transfusion, hyperkalemia, and heart failure in advanced chronic kidney disease.

Gill K, Fink JC, Gilbertson DT, Monda KL, Muntner P, Lafayette RA, Petersen J, Chertow GM, Bradbury BD.

Pharmacoepidemiol Drug Saf. 2015 Jun;24(6):654-62. doi: 10.1002/pds.3779. Epub 2015 Apr 22.

PMID:
25903095
25.

Mapping novel immunogenic epitopes in IgA nephropathy.

Woo SH, Sigdel TK, Dinh VT, Vu MT, Sarwal MM, Lafayette RA.

Clin J Am Soc Nephrol. 2015 Mar 6;10(3):372-81. doi: 10.2215/CJN.02390314. Epub 2014 Dec 26.

26.

Incidence and relevance of proteinuria in bevacizumab-treated patients: pooled analysis from randomized controlled trials.

Lafayette RA, McCall B, Li N, Chu L, Werner P, Das A, Glassock R.

Am J Nephrol. 2014;40(1):75-83. doi: 10.1159/000365156. Epub 2014 Jul 18.

PMID:
25059491
27.

Maternal proteinuria in twin compared with singleton pregnancies.

Osmundson SS, Lafayette RA, Bowen RA, Roque VC, Garabedian MJ, Aziz N.

Obstet Gynecol. 2014 Aug;124(2 Pt 1):332-7. doi: 10.1097/AOG.0000000000000383.

PMID:
25004349
28.

Anemia management trends in hospital-based dialysis centers (HBDCs), 2010 to 2013.

Coritsidis GN, Maglinte GA, Acharya A, Saxena A, Chang CL, Hill J, Gitlin M, Lafayette RA.

Clin Ther. 2014 Mar 1;36(3):408-18. doi: 10.1016/j.clinthera.2014.01.015. Epub 2014 Feb 28.

PMID:
24582713
29.

Renal function in normal and disordered pregnancy.

Hussein W, Lafayette RA.

Curr Opin Nephrol Hypertens. 2014 Jan;23(1):46-53. doi: 10.1097/01.mnh.0000436545.94132.52.

30.

Implantable cardioverter-defibrillator placement in patients with cardiac amyloidosis.

Varr BC, Zarafshar S, Coakley T, Liedtke M, Lafayette RA, Arai S, Schrier SL, Witteles RM.

Heart Rhythm. 2014 Jan;11(1):158-62. doi: 10.1016/j.hrthm.2013.10.026. Epub 2013 Oct 10. No abstract available.

PMID:
24121001
31.

Immunoglobulin A nephropathy: insights and progress.

Lafayette RA.

Transl Res. 2014 Jan;163(1):3-7. doi: 10.1016/j.trsl.2013.08.007. Epub 2013 Sep 21. No abstract available.

PMID:
24064200
32.

Treatment of idiopathic FSGS with adrenocorticotropic hormone gel.

Hogan J, Bomback AS, Mehta K, Canetta PA, Rao MK, Appel GB, Radhakrishnan J, Lafayette RA.

Clin J Am Soc Nephrol. 2013 Dec;8(12):2072-81. doi: 10.2215/CJN.02840313. Epub 2013 Sep 5.

33.

High-potency statins and acute kidney injury-associated hospitalizations.

Lenihan CR, Lafayette RA.

Am J Kidney Dis. 2013 Nov;62(5):877-9. doi: 10.1053/j.ajkd.2013.07.006. Epub 2013 Aug 22. No abstract available.

34.

Renal physiology of pregnancy.

Cheung KL, Lafayette RA.

Adv Chronic Kidney Dis. 2013 May;20(3):209-14. doi: 10.1053/j.ackd.2013.01.012. Review.

35.

Red blood cell transfusion use in patients with chronic kidney disease.

Gill KS, Muntner P, Lafayette RA, Petersen J, Fink JC, Gilbertson DT, Bradbury BD.

Nephrol Dial Transplant. 2013 Jun;28(6):1504-15. doi: 10.1093/ndt/gfs580. Epub 2013 Feb 6.

PMID:
23389999
36.

More than a frog in the throat: a case series and review of localized laryngeal amyloidosis.

Stevenson R, Witteles R, Damrose E, Arai S, Lafayette RA, Schrier S, Afghahi A, Liedtke M.

Arch Otolaryngol Head Neck Surg. 2012 May;138(5):509-11. doi: 10.1001/archoto.2012.423. Review. No abstract available.

PMID:
22652951
37.

Profiling of autoantibodies in IgA nephropathy, an integrative antibiomics approach.

Sigdel TK, Woo SH, Dai H, Khatri P, Li L, Myers B, Sarwal MM, Lafayette RA.

Clin J Am Soc Nephrol. 2011 Dec;6(12):2775-84. doi: 10.2215/CJN.04600511.

38.

Heart transplantation and cardiac amyloidosis: approach to screening and novel management strategies.

Varr BC, Liedtke M, Arai S, Lafayette RA, Schrier SL, Witteles RM.

J Heart Lung Transplant. 2012 Mar;31(3):325-31. doi: 10.1016/j.healun.2011.09.010. Epub 2011 Nov 3.

PMID:
22051505
39.

Serum relaxin levels and kidney function in late pregnancy with or without preeclampsia.

Lafayette RA, Hladunewich MA, Derby G, Blouch K, Druzin ML, Myers BD.

Clin Nephrol. 2011 Mar;75(3):226-32.

PMID:
21329633
40.

Hemoglobinuria and acute kidney injury requiring hemodialysis following intravenous immunoglobulin infusion.

Welles CC, Tambra S, Lafayette RA.

Am J Kidney Dis. 2010 Jan;55(1):148-51. doi: 10.1053/j.ajkd.2009.06.013. Epub 2009 Jul 23.

PMID:
19628320
41.

Imatinib in the treatment of nephrogenic systemic fibrosis.

Chandran S, Petersen J, Jacobs C, Fiorentino D, Doeden K, Lafayette RA.

Am J Kidney Dis. 2009 Jan;53(1):129-32. doi: 10.1053/j.ajkd.2008.08.029. Epub 2008 Nov 13.

PMID:
19012999
42.

Facility factors dominate the ability to achieve target haemoglobin levels in haemodialysis patients.

Chan KE, Lafayette RA, Whittemore AS, Hlatky MA, Moran J.

Nephrol Dial Transplant. 2008 Sep;23(9):2948-56. doi: 10.1093/ndt/gfn172. Epub 2008 May 9.

PMID:
18469314
43.

Course of preeclamptic glomerular injury after delivery.

Hladunewich MA, Myers BD, Derby GC, Blouch KL, Druzin ML, Deen WM, Naimark DM, Lafayette RA.

Am J Physiol Renal Physiol. 2008 Mar;294(3):F614-20. doi: 10.1152/ajprenal.00470.2007. Epub 2008 Jan 16.

44.

Prediction of early progression in recently diagnosed IgA nephropathy.

Lemley KV, Lafayette RA, Derby G, Blouch KL, Anderson L, Efron B, Myers BD.

Nephrol Dial Transplant. 2008 Jan;23(1):213-22. Epub 2007 Sep 22.

PMID:
17890749
45.

Effect of L-arginine therapy on the glomerular injury of preeclampsia: a randomized controlled trial.

Hladunewich MA, Derby GC, Lafayette RA, Blouch KL, Druzin ML, Myers BD.

Obstet Gynecol. 2006 Apr;107(4):886-95.

PMID:
16582128
46.

Associations of serologic markers of infection and inflammation with vascular disease events and mortality in American dialysis patients.

Lentine KL, Parsonnet J, Taylor I, Wrone EM, Lafayette RA.

Clin Exp Nephrol. 2006 Mar;10(1):55-62.

PMID:
16544178
47.

Renal tubular injury associated with anagrelide use.

Rodwell GE, Troxell ML, Lafayette RA.

Nephrol Dial Transplant. 2005 May;20(5):988-90. Epub 2005 Feb 22. No abstract available.

PMID:
15728271
48.

Examining chronic kidney disease management in a single center.

Lafayette RA, Lai G.

Clin Nephrol. 2004 Oct;62(4):260-6.

PMID:
15524055
49.

The dynamics of glomerular filtration in the puerperium.

Hladunewich MA, Lafayette RA, Derby GC, Blouch KL, Bialek JW, Druzin ML, Deen WM, Myers BD.

Am J Physiol Renal Physiol. 2004 Mar;286(3):F496-503. Epub 2003 Nov 11.

50.

Podocytopenia and disease severity in IgA nephropathy.

Lemley KV, Lafayette RA, Safai M, Derby G, Blouch K, Squarer A, Myers BD.

Kidney Int. 2002 Apr;61(4):1475-85.

Supplemental Content

Loading ...
Support Center